Meeting
2015 ASCO Annual Meeting
Elevated blood pressure (BP) and adverse events (AEs) of hypertension (HTN) in ponatinib (PON) leukemia trials.
Authors
Hanna Jean Khoury
Winship Cancer Institute of Emory University, Atlanta, GA
Hanna Jean Khoury , Michele Baccarani , Francois Guilhot , Andreas Hochhaus , Timothy P. Hughes , Jeffrey Howard Lipton , Stephanie Lustgarten , Kumiko Yanase , Maureen G Conlan , Jorge E. Cortes , Michael W.N. Deininger , Hagop M. Kantarjian , Neil P. Shah , Moshe Talpaz , Michael J. Mauro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT00660920; NCT01207440; NCT01650805
Citation
J Clin Oncol 33, 2015 (suppl; abstr 7049)
DOI
10.1200/jco.2015.33.15_suppl.7049
Abstract #
7049
Poster Bd #
38
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.
First Author: Jorge E. Cortes
Poster
2020 ASCO Virtual Scientific Program
An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia.
First Author: James L Januzzi
Poster
2017 ASCO Annual Meeting
Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).
First Author: Hagop M. Kantarjian
Poster
2014 ASCO Annual Meeting
Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.
First Author: Hagop M. Kantarjian